Sharehldg in IntegriSys Ltd

Billam PLC
6 June 2001


                                BILLAM PLC

          Sale and purchase of ordinary shares in IntegriSys Limited

                          to World Life Sciences plc


Billam Plc has today sold 6,000 B Ordinary shares in IntegriSys Limited ('
IntegriSys'), representing 4% of the issued share capital, at a price of £
83.33 per share to World Life Sciences plc ('WLS'), a company which is 42%
owned by Billam AG, a wholly owned subsidiary of Billam plc.  WLS currently
has no interest in IntegriSys.  The total consideration for the acquisition is
£499,980 payable in cash, valuing IntegriSys at £12.5 million.  Billam will
retain an interest of approximately 2.7% in IntegriSys.

At the same time, the existing shareholders of IntegriSys, including Billam
Plc and a venture capital fund, MTI, will be increasing their investment in
IntegriSys by a further £303,000 each, also at a price of £83.33 per share.

IntegriSys offers a biomedical information delivery structure.  It supplies
information to doctor's computer screens from medical databases and other
sources.  Using internet push technology, it can deliver data and provide an
audit trail. For the 12 months to 30 April 2001, the end of the product
development stage, the unaudited management accounts show IntegriSys made a
pre-tax loss of £1,214,186 and had net liabilities of £256,377, having
written-off all development costs.

The investment by Billam and MTI constitutes a mezzanine round of finance in
advance of a full second round of funding which is planned for the end of this
year at price which is anticipated to be not less that £83.33 per share.

The sale of shares in IntegriSys is classified as a related party transaction
under the AIM Rules.  The independent director of Billam considers that,
having consulted with Peel Hunt plc, the terms of the transaction are fair and
reasonable insofar as shareholders of Billam are concerned.


For further information please contact: Peter Hoskins 020 7702 5544